Search

The article presents answers to questions related to lutetium-177-PSMA-617 therapy for metastatic castration-resistant prostate cancer based on a randomized controlled trial.

The article focuses on the additional information provided by three authors of American Society of Clinical Oncology 's guideline on the management of metastatic clear cell renal cell carcinoma (mRCC) regarding cytoreductive nephrectomy, preferred options for first-line systemic treatment, and optimal second or later line systemic treatment. It also mentions the role of cytoreductive nephrectomy should be considered for patients with intermediate-risk disease.

The article presents a clinical practice guideline summary from the American Society of Clinical Oncology (ASCO) on the optimum imaging options that should be offered to patients with advanced prostate cancer. Topics covered include the target population of the imaging options, the method used to develop the guideline recommendations, and the recommended imaging options for patients with different disease states and clinicopathologic factors.

The article offers information on the clinical practice guideline from the American Society of Clinical Oncology (ASCO) on metastatic non-castrate prostate cancer treatment. Topics include guideline question, target population and audience, and recommendations for treatment with Androgen Deprivation Therapy (ADT) Plus Docetaxel and ADT Plus Abiraterone.

The article presents the American Society of Clinical Oncology's (ASCO) Clinical Practice Guideline Summary for women with hormone receptor-positive metastatic breast cancer who are candidates for endocrine therapy. Topics discussed include the prevalence of breast cancer among women in developed countries, options for endocrine therapy, and the problem with the treatment of premenopausal women in regard to ovarian suppression and optimal use of hormone agents.

The article presents guidelines on muscle-invasive (MIBC) and metastatic bladder cancer. Topics include the endorsement of the guidelines from the European Association of Urology (EAU) by the American Society of Clinical Oncology (ASCO), the inclusion of neoadjuvant chemotherapy, and the use of radical cystectomy and chemoradiation-based organ preservation.

The article presents the update by the American Society of Clinical Oncology on the potential of RAS gene mutation testing in forecasting reactions to anti-epidermal growth factor receptor monoclonal antibody among patients with metastatic colorectal carcinoma. Topics discussed include the study was done on systematic reviews comparing the antibodies to standard therapy, and essential mutations to be checked on the therapy like KRAS and NRAS exons.

The article offers a summary of the Clinical Practice Guideline (CPG) on the management of patients with metastatic castration-resistant prostate cancer (CRPC). The guideline was based on the recommendations from the Cancer Care Ontario (CCO) and the American Society of Clinical Oncology (ASCO). The authors of the guideline are mentioned which include Ethan Basch, Thomas K. Oliver and Michael Carducci.

The article presents an answer to a question about targeted therapy to treat women with metastatic human epidermal growth factor receptor 2 (HER2) breast cancer.